RxDoctor Payments DataLook up a doctor →

Mila Ioussifova, OD

Optometrist · Portland, ORNPI 1821282609

Payments from drug & device makers

$222,927in general payments, 2019–2025

Across 590 payments — averaging $377.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$73K
  • Sun Pharmaceutical Industries Inc.$63K
  • Bausch & Lomb Americas Inc.$51K
  • Lumenis BE Inc$14K
  • Biotissue Holdings Inc.$8K
  • Tarsus Pharmaceuticals, Inc.$6K
  • plus $8K from 18 others

What the payments were for

  • Consulting fees$25,12511%
  • Speaking & faculty fees$136,66561%
  • Travel & lodging$35,64016%
  • Food & beverage$25,40811%
  • Education$360%
  • Gifts$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222,927 in reported general payments places this provider in the 95th percentile of 684 optometrist providers in Oregon.

See all optometrist providers in Oregon

Medicare billing

Part B allowed, 2024
$22,028
Medicare patients
59
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf37$38,123
XdemvyLotilaner18$33,310
RestasisCyclosporine11$17,092
CequaCyclosporine13$11,203
Loteprednol Etabonate14$2,332
Prednisolone Acetate13$460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo$51,402$38,12337 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$5,604$33,31018 claims
AbbVieRestasis$2,133$17,09211 claims
Sun Pharmaceutical Industries Inc.Cequa$62,926$11,20313 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$12$2,33214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 684 optometrist providers in Oregon.

Other optometrist in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →